Cargando…

Chromosome instability and benefit from adjuvant anthracyclines in breast cancer

BACKGROUND: Duplication of the centromeric region of chromosome 17 (Ch17CEP) is associated with sensitivity to anthracyclines. An explanation may be chromosome instability (CIN); a frequent event in solid tumours associated with poor outcome. The predictive value of CIN seems to be drug dependent an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Munro, A F, Twelves, C, Thomas, J S, Cameron, D A, Bartlett, J MS
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3389422/ https://www.ncbi.nlm.nih.gov/pubmed/22644297 http://dx.doi.org/10.1038/bjc.2012.232

Ejemplares similares

Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?
por: Munro, Alison F, et al.
Publicado: (2013)

A four gene signature predicts benefit from anthracyclines: evidence from the BR9601 and MA.5 clinical trials
por: Spears, Melanie, et al.
Publicado: (2015)

Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy
por: Timotheadou, Eleni, et al.
Publicado: (2017)

Cardiac mechanisms for low aerobic power in anthracycline treated, older, long-term breast cancer survivors
por: Beaudry, Rhys I., et al.
Publicado: (2022)

Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: A post hoc pooled analysis
por: Cortes, Javier, et al.
Publicado: (2019)

Anthracycline and concurrent radiotherapy as adjuvant treatment of operable breast cancer: a retrospective cohort study in a single institution
por: Ismaili, Nabil, et al.
Publicado: (2010)

Chromosome instability in fibroblasts derived from Li–Fraumeni syndrome families without TP53 mutations
por: Boyle, J M, et al.
Publicado: (2000)

Anthracycline-induced cytotoxicity in the GL261 glioma model system
por: Tavener, Amber M., et al.
Publicado: (2021)

Successful reduction of alopecia induced by anthracycline and taxane containing adjuvant chemotherapy in breast cancer – clinical evaluation of sensor-controlled scalp cooling
por: Friedrichs, Kay, et al.
Publicado: (2014)

Excessive centrosome abnormalities without ongoing numerical chromosome instability in a Burkitt's lymphoma
por: Duensing, Stefan, et al.
Publicado: (2003)

Chromosomal instability correlates with poor outcome in patients with myelodysplastic syndromes irrespectively of the cytogenetic risk group
por: Heilig, Christoph E, et al.
Publicado: (2010)

Juvenile competitive triathlete after cardiotoxic anthracycline therapy for Acute Myeloid Leukemia
por: von Korn, Pia, et al.
Publicado: (2016)

Anthracycline doses in patients with liver dysfunction: do UK oncologists follow current recommendations?
por: Dobbs, N. A., et al.
Publicado: (1998)

Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines
por: Berruti, A, et al.
Publicado: (2005)

Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancer
por: Braunstein, Marsela, et al.
Publicado: (2016)

The role of MYH and microsatellite instability in the development of sporadic colorectal cancer
por: Colebatch, A, et al.
Publicado: (2006)

Adjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysis
por: Petrelli, Fausto, et al.
Publicado: (2022)

The comparison of anthracycline-based and non-anthracycline-based regimens in adjuvant chemotherapy of HER2-positive non-metastatic breast cancers
por: Najafi, Safa, et al.
Publicado: (2018)

The Impact of Adding Taxanes to Anthracyclines on Women with Breast Cancer Receiving Adjuvant Chemotherapy
por: Hilaj, Erina, et al.
Publicado: (2020)

Sequential vs concurrent adjuvant chemotherapy of anthracycline and taxane for operable breast cancer
por: Chen, Wanjing, et al.
Publicado: (2021)

Prognostic impact of microsatellite instability in gastric cancer
por: Zepeda-Najar, Cesar, et al.
Publicado: (2021)

Characterization of antigen adjuvant interactions in polyacrylate adjuvanted vaccines
por: Dinadayala, Premkumar, et al.
Publicado: (2022)

HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients
por: Del Mastro, L, et al.
Publicado: (2005)

Plasma levels of Semaphorin 4D are decreased by adjuvant tamoxifen but not aromatase inhibitor therapy in breast cancer patients
por: Göbel, Andy, et al.
Publicado: (2019)

Chromosomal instability in the pathogenesis and treatment of breast cancer
por: Venkitaraman, A
Publicado: (2008)

Chromosome 17 Centromere Duplication and Responsiveness to Anthracycline-Based Neoadjuvant Chemotherapy in Breast Cancer()()
por: Tibau, Ariadna, et al.
Publicado: (2014)

Clinical Characteristics and Outcome Trends of Adjuvant Anthracycline and Taxane Regimen for Early Stage Breast Cancer
por: Vaid, Ashok K., et al.
Publicado: (2020)

Chromosomal instability in the lymphocytes of breast cancer patients
por: Harsimran, Kaur, et al.
Publicado: (2009)

Mapping of balanced chromosome translocation breakpoints to the basepair level from microdissected chromosomes
por: Obenauf, Anna C, et al.
Publicado: (2010)

Exercise to Reduce Anthracycline-Mediated Cardiovascular Complications in Breast Cancer Survivors
por: Varghese, Sonu S., et al.
Publicado: (2021)

Measuring perceived benefit and disease-related burden in young cancer survivors: validation of the Benefit and Burden Scale for Children (BBSC) in the Netherlands
por: Maurice-Stam, Heleen, et al.
Publicado: (2011)

Misaligned Chromosomes are a Major Source of Chromosomal Instability in Breast Cancer
por: Tucker, John B., et al.
Publicado: (2023)

Differential Response of Immunohistochemically Defined Breast Cancer Subtypes to Anthracycline-Based Adjuvant Chemotherapy with or without Paclitaxel
por: Fountzilas, George, et al.
Publicado: (2012)

Extended follow-up of breast cancer patients in clinic wastes time for both patients and doctors: the case against
por: Cameron, David A
Publicado: (2008)

The Tabby cat locus maps to feline chromosome B1
por: Lyons, L A, et al.
Publicado: (2006)

A four gene signature of chromosome instability (CIN4) predicts for benefit from taxanes in the NCIC-CTG MA21 clinical trial
por: Spears, Melanie, et al.
Publicado: (2016)

Adjuvant treatment: the contribution of expression microarrays
por: Lønning, Per Eystein, et al.
Publicado: (2007)

Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel
por: Berliere, Martine, et al.
Publicado: (2008)

Incidence of Chemotherapy-Induced Amenorrhea After Adjuvant Chemotherapy With Taxane and Anthracyclines in Young Patients With Breast Cancer
por: Pourali, Leila, et al.
Publicado: (2013)

Anthracycline versus nonanthracycline adjuvant therapy for early breast cancer: A systematic review and meta-analysis
por: Ding, Wu, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_109b3qg5aupse591tg3ge96aur